51 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late http://www.zacks.com/stock/news/537152/heres-why-sanofi-sny-is-outperforming-its-industry-of-late?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-537152 Sep 26, 2019 - Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug http://www.zacks.com/stock/news/539107/abbvie-abbv-gets-fda-nod-for-label-expansion-of-hcv-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539107 Sep 27, 2019 - AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data http://www.zacks.com/stock/news/544876/immunomedics-immu-reports-interim-urothelial-cancer-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-544876 Oct 01, 2019 - Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA http://www.zacks.com/stock/news/545656/astrazenecas-triple-combo-copd-inhaler-gets-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545656 Oct 02, 2019 - AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY http://www.zacks.com/stock/news/549246/pharma-stock-roundup-jnjs-opioid-settlement-fda-updates-for-azn-gsk-mrk-rhhby?cid=CS-ZC-FT-analyst_blog|stock_roundup-549246 Oct 04, 2019 - J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion http://www.zacks.com/stock/news/549197/gileads-descovy-hiv-regimen-gets-fda-nod-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-549197 Oct 04, 2019 - Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
Top Analyst Reports for General Dynamics, Merck & Progressive http://www.zacks.com/research-daily/549253/top-analyst-reports-for-general-dynamics-merck-progressive?cid=CS-ZC-FT-research_daily-549253 Oct 07, 2019 - Top Analyst Reports for General Dynamics, Merck & Progressive
5 Dow Stocks Poised to Beat on Earnings This Month http://www.zacks.com/stock/news/570902/5-dow-stocks-poised-to-beat-on-earnings-this-month?cid=CS-ZC-FT-analyst_blog|investment_ideas-570902 Oct 18, 2019 - Despite severe market volatility, the Dow is still in positive territory with a gain of 15.9% year to date. This is an excellent performance after a disappointing 2018.
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings http://www.zacks.com/stock/news/571262/factors-setting-the-tone-for-novartis-nvs-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-571262 Oct 18, 2019 - Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
What's in Store for Healthcare ETFs in Q3 Earnings? http://www.zacks.com/stock/news/575582/whats-in-store-for-healthcare-etfs-in-q3-earnings?cid=CS-ZC-FT-etf_news_and_commentary-575582 Oct 21, 2019 - With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.

Pages: 123456

<Page 2>